Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.

Pallocca M, Angeli D, Palombo F, Sperati F, Milella M, Goeman F, De Nicola F, Fanciulli M, Nisticò P, Quintarelli C, Ciliberto G.

J Transl Med. 2019 Apr 23;17(1):131. doi: 10.1186/s12967-019-1865-8.

2.

PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?

Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M, Ciuffreda L.

Cancers (Basel). 2019 Mar 28;11(4). pii: E435. doi: 10.3390/cancers11040435. Review.

3.

Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases.

Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis ML, Addario A, Costantini M, Flex E, Ciolfi A, Pizzi S, Bruselles A, Pallocca M, Simone G, Haoui M, Falchi M, Milella M, Sentinelli S, Di Matteo P, Stellacci E, Gallucci M, Muto G, Tartaglia M, De Maria R, Bonci D.

Cell Death Dis. 2019 Feb 27;10(3):201. doi: 10.1038/s41419-019-1453-0.

4.

Reverse Engineering Cancer: Inferring Transcriptional Gene Signatures from Copy Number Aberrations with ICAro.

Angeli D, Fanciulli M, Pallocca M.

Cancers (Basel). 2019 Feb 22;11(2). pii: E256. doi: 10.3390/cancers11020256.

5.

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.

Aurisicchio L, Salvatori E, Lione L, Bandini S, Pallocca M, Maggio R, Fanciulli M, De Nicola F, Goeman F, Ciliberto G, Conforti A, Luberto L, Palombo F.

J Exp Clin Cancer Res. 2019 Feb 14;38(1):78. doi: 10.1186/s13046-019-1084-4.

6.

The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression.

Buglioni S, Melucci E, Sperati F, Pallocca M, Terrenato I, De Nicola F, Goeman F, Casini B, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vici P, Sergi D, Pizzuti L, Di Lauro L, Mazzotta M, Barba M, Fanciulli M, Vitale I, De Maria R, Ciliberto G, Maugeri-Saccà M.

Oncoimmunology. 2018 Apr 24;7(8):e1457602. doi: 10.1080/2162402X.2018.1457602. eCollection 2018.

7.

Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model.

Belloni L, Di Cocco S, Guerrieri F, Nunn ADG, Piconese S, Salerno D, Testoni B, Pulito C, Mori F, Pallocca M, Sacconi A, Vivoli E, Marra F, Strano S, Blandino G, Levrero M, Pediconi N.

Sci Rep. 2018 Sep 11;8(1):13638. doi: 10.1038/s41598-018-31835-2.

8.

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.

Pallocca M, Goeman F, De Nicola F, Melucci E, Sperati F, Terrenato I, Pizzuti L, Casini B, Gallo E, Amoreo CA, Vici P, Di Lauro L, Buglioni S, Diodoro MG, Pescarmona E, Mazzotta M, Barba M, Fanciulli M, De Maria R, Ciliberto G, Maugeri-Saccà M.

J Transl Med. 2018 Sep 4;16(1):247. doi: 10.1186/s12967-018-1607-3.

9.

Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer.

De Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, Casini B, Amoreo CA, Gallo E, Diodoro MG, Buglioni S, Mazzotta M, Vici P, Sergi D, Di Lauro L, Barba M, Pescarmona E, Ciliberto G, De Maria R, Fanciulli M, Maugeri-Saccà M.

Oncogenesis. 2018 Jul 22;7(7):55. doi: 10.1038/s41389-018-0066-2.

10.

The perfect personalized cancer therapy: cancer vaccines against neoantigens.

Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.

J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1. Review.

11.

Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Di Agostino S, Valenti F, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, Ganci F, Muti P, Strano S, Blandino G.

Theranostics. 2018 Feb 12;8(7):1850-1868. doi: 10.7150/thno.22167. eCollection 2018.

12.

Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.

Melucci E, Casini B, Ronchetti L, Pizzuti L, Sperati F, Pallocca M, De Nicola F, Goeman F, Gallo E, Amoreo CA, Sergi D, Terrenato I, Vici P, Di Lauro L, Diodoro MG, Pescarmona E, Barba M, Mazzotta M, Mottolese M, Fanciulli M, Ciliberto G, De Maria R, Buglioni S, Maugeri-Saccà M.

J Transl Med. 2018 Feb 5;16(1):22. doi: 10.1186/s12967-018-1385-y.

13.

Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.

Folgiero V, Sorino C, Pallocca M, De Nicola F, Goeman F, Bertaina V, Strocchio L, Romania P, Pitisci A, Iezzi S, Catena V, Bruno T, Strimpakos G, Passananti C, Mattei E, Blandino G, Locatelli F, Fanciulli M.

EMBO Rep. 2018 Mar;19(3). pii: e44871. doi: 10.15252/embr.201744871. Epub 2018 Jan 24.

14.

Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.

Sette G, Salvati V, Giordani I, Pilozzi E, Quacquarini D, Duranti E, De Nicola F, Pallocca M, Fanciulli M, Falchi M, Pallini R, De Maria R, Eramo A.

Int J Cancer. 2018 Jul 1;143(1):88-99. doi: 10.1002/ijc.31260. Epub 2018 Jan 26.

PMID:
29341112
15.

BCL-XL overexpression promotes tumor progression-associated properties.

Trisciuoglio D, Tupone MG, Desideri M, Di Martile M, Gabellini C, Buglioni S, Pallocca M, Alessandrini G, D'Aguanno S, Del Bufalo D.

Cell Death Dis. 2017 Dec 13;8(12):3216. doi: 10.1038/s41419-017-0055-y.

16.

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Pallocca M, Amoreo CA, Sperati F, Di Franco S, Barresi S, Policicchio E, De Luca G, De Nicola F, Mottolese M, Zeuner A, Fanciulli M, Stassi G, Maugeri-Saccà M, Baiocchi M, Tartaglia M, Vitale I, De Maria R.

Gut. 2018 May;67(5):903-917. doi: 10.1136/gutjnl-2016-312623. Epub 2017 Apr 7.

17.

DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.

Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P, Sergi D, Di Lauro L, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vitale I, Barba M, Buglioni S, Mottolese M, Fanciulli M, De Maria R, Maugeri-Saccà M.

Int J Cancer. 2017 Jun 1;140(11):2587-2595. doi: 10.1002/ijc.30668. Epub 2017 Mar 11.

18.

Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization.

Bruno T, Valerio M, Casadei L, De Nicola F, Goeman F, Pallocca M, Catena V, Iezzi S, Sorino C, Desantis A, Manetti C, Blandino G, Floridi A, Fanciulli M.

J Exp Clin Cancer Res. 2017 Feb 18;36(1):32. doi: 10.1186/s13046-017-0497-1.

19.

Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.

Catena V, Bruno T, De Nicola F, Goeman F, Pallocca M, Iezzi S, Sorino C, Cigliana G, Floridi A, Blandino G, Fanciulli M.

Oncotarget. 2016 Oct 25;7(43):70546-70558. doi: 10.18632/oncotarget.12060.

20.

Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects.

Mori F, Ferraiuolo M, Santoro R, Sacconi A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P, Blandino G, Strano S.

Oncotarget. 2016 Apr 12;7(15):20532-48. doi: 10.18632/oncotarget.7978.

Supplemental Content

Loading ...
Support Center